{"entity":{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","aka":[],"tldr":"Senior author of the UK's two standard-setting biliary trials, ABC-02 and BILCAP, chief investigator of ABC-06, and UK lead of the first-line precision medicine trial SAFIR-ABC10.","summary":"John Bridgewater is professor of medical oncology at the UCL Cancer Institute and a consultant at UCLH. He was senior author on ABC-02 (gemcitabine plus cisplatin as first-line standard) and BILCAP (adjuvant capecitabine), chief investigator of ABC-06 (second-line FOLFOX) and leads the National Cancer Research Institute biliary tract subgroup. He leads the UK arm of SAFIR-ABC10, sponsored by UCL and UCLH, which profiles tumours and matches patients with cholangiocarcinoma or gallbladder cancer to one of seven targeted therapies, and co-authored the 2023 British Society of Gastroenterology cholangiocarcinoma guideline.","asOf":"2026-09-24","links":[{"label":"UCL profile","url":"https://profiles.ucl.ac.uk/824-john-bridgewater"},{"label":"UCLH consultant page","url":"https://www.uclh.nhs.uk/our-services/find-consultant/professor-john-bridgewater"}],"tags":["biliary","trialist","uk"],"related":["mairead-mcnamara"],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","gemcitabine","cisplatin"],"companies":[],"institutions":["uclh","ammf"],"pathways":[],"terms":[],"trials":["abc-02","abc-06","bilcap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, UCL Cancer Institute; Consultant Medical Oncologist, University College London Hospitals; Medical Adviser, AMMF","institutionId":"uclh","specialisms":["Biliary tract cancer","Carcinoma of unknown primary","Gastrointestinal oncology","Precision medicine trials"],"profiles":[{"label":"UCL profile","url":"https://profiles.ucl.ac.uk/824-john-bridgewater"},{"label":"UCLH consultant page","url":"https://www.uclh.nhs.uk/our-services/find-consultant/professor-john-bridgewater"}],"papers":[{"title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP)","journal":"Lancet Oncology","year":2019,"doi":"10.1016/S1470-2045(18)30915-X"},{"title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06)","journal":"Lancet Oncology","year":2021,"doi":"10.1016/S1470-2045(21)00027-9"},{"title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","journal":"Gut","year":2023,"doi":"10.1136/gutjnl-2023-330029"}]},"route":"/people/john-bridgewater/","neighbours":{"person":[{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/"}],"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"institution":[{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/"},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/"}],"trial":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/"},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/"}]}}